Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 6, 2024HaematologicaOpen Access

Superior outcomes and high-risk features with carfilzomib, lenalidomide, and dexamethasone combination therapy for patients with relapsed and refractory multiple myeloma: Results of the multicenter KMMWP2201 study

View Full Paper
Ask AI
Bookmark
Share

Authors

JLJi Hyun LeeJCJimin ChoiCMChang‐Ki Min

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Lee et al. (2024) studied this question.

synapsesocial.com/papers/68e65d18b6db6435875eb6dbhttps://doi.org/10.3324/haematol.2024.285534
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma2021 · 2,564 citations
  2. 2Incorporating hematopoietic stem-cell transplantation after second-line carfilzomib-lenalidomide-dexamethasone (KRd)2020 · 3 citations
  3. 3Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma2012 · 1,159 citations
  4. 4Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trial2021 · 78 citations
  5. 5Real‐world use of carfilzomib combined with lenalidomide and dexamethasone in patients with multiple myeloma in Europe and Israel2022 · 10 citations